Connexion

LECA V

Email : -
Membre du laboratoire : Non
Organisme : -
Equipes : -
Références (3)
ACL Greillier L, Monville F, Leca V, Vely F, Garcia-Filipe S, Ciccolini J, Sabatier F, Ferrani G, Boudai N, Ghezali L, Landri M, Marin C, Hamimed M, Arnaud L, Karlsen M, Atsou K, Bokobza S, Fleury P, Boyer A, Audigier-Valette C, Martinez S, Pegliasco H, Ray P, Falchero L, Serre A, Cloarec N, Lebas L, Hominal S, Barré P, Zahi S, Frikha A, Bory P, Ray ML, Laborde L, Martin V, Malkoun R, Roumieux M, Mazieres J, Pérol M, Vivier E, Benzekry S, Fieschi J, Barlesi F (2022) Abstract LB120: Comprehensive biomarkers analysis to explain resistances to PD1-L1 ICIs: The precision immuno-oncology for advanced non-small cell lung cancer (PIONeeR) trial. Cancer res 82 | doi: 10.1158/1538-7445.AM2022-LB120

ACL Ghezali L, Landri M, Monville F, Leca V, Vasse T, Hamdad C, Mercadal M, Vanhille L, Kassambara A, Sbarrato T, Le Ray M, Roumieux M, Malkoun R, Resseguier N, Boyer A, Audigier-Valette C, Martinez S, Pegliasco H, Ray P, Falchero L, Serre A, Cloarec N, Lebas L, Hominal S, Barré P, Zahi S, Frikha A, Bory P, Laborde L, Mazières J, Martin V, Mazières J, Pérol M, Greillier L, Barlesi F, Fieschi J (2022) Brightplex® TCE and brightplex® MDSC assays combination improves advanced NSCLC patients’ stratification under anti-PD1/L1 immunotherapy in the PIONeeR project. J immunotherap cancer 10 | doi: 10.1136/jitc-2022-SITC2022.0701